Achieve names CPA Halladay as CFO to accelerate cytisinicline plans
Oct 1, 2026, 9:45 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
A CFO hire with proven public-company finance and large-deal experience can reduce execution risk and improve capital planning, potentially supporting a favorable view on cytisinicline commercialization timelines and NDA risk. Historical precedent shows skilled financial leadership can unlock more favorable financing and partnerships during late-stage development.
AI summary
What happened, with direct paths to the underlying reporting
Achieve Life Sciences named Benjamin Halladay, CPA, as CFO, effective Oct 5, 2026, replacing Mark Oki. Halladay previously served as CFO at Esperion, guiding deleveraging and a sale to ARCHIMED for up to $1.1 billion. As cytisinicline NDA resubmission nears, the leadership change aims to strengthen capital planning and execution.
Achieve names Benjamin Halladay, CPA, as CFO, effective Oct 5, 2026.
Halladay previously CFO at Esperion, led deleveraging and a sale to ARCHIMED.
Mark Oki steps down; Halladay succeeds him as CFO.
NDA resubmission timing for cytisinicline remains a key milestone.
Cytisinicline Breakthrough Therapy designation supports Achieve's development plan.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Achieve Life Sciences said the FDA declined to approve its nicotine-dependence drug for adults, representing a regulatory setback that blocks near-term US commercialization. The o…
ACHV is seeking FDA approval for cytisinicline, targeting 2026 launch. HC Wainwright has initiated coverage with a Buy rating and $12 price target. Cytisinicline shows greater eff…
